♥ HF Guideline NavigatorESC 2026

3

3 Definition, epidemiology and classifications

Pages 15–19 · open in PDF

Text below is machine-extracted from the PDF page(s) listed; two-column layouts and tables can read out of order, and neighbouring sections on the same page are included. Use the PDF link for the authoritative layout.

Page 15 · PDF

In cases of a clear association between paroxysmal or persistent AF and worsening of HF symptoms, which persist despite MT, catheter ablation should be considered for the prevention or treatment of AF.

Catheter ablation for AF should be considered in IIa

angina, despite FMT for HF and antianginal drugs, to relieve symptoms.

antianginal drugs. Aortic valve intervention, TAVI or SAVR, is

Aortic valve intervention, SAVR or TAVI, is

recommended in patients with HF and severe

recommended in patients with severe aortic

high-gradient aortic stenosis to reduce mortality and improve symptoms.

Percutaneous edge-to-edge mitral valve repair should be considered in carefully selected patients

Mitral transcatheter edge-to-edge repair is recommended in haemodynamically stable,

with secondary mitral regurgitation, not eligible for surgery and not needing coronary revascularization, who are symptomatic despite

stenosis and HF to improve symptoms and reduce the risk of death.

symptomatic patients with HFrEF and persistent IIa

severe secondary mitral regurgitation despite optimized FMT and CRT if indicated, who fulfil

OMT and who fulfil criteria for achieving a

specific clinical and echocardiographic criteria, in

reduction in HF hospitalizations.

order to reduce the risk of HFH and improve QoL.

Multidisciplinary management—Section 11 Monitoring of pulmonary artery pressure using a wireless haemodynamic monitoring system may be considered in symptomatic patients with HF in order to improve clinical outcomes.

Remote haemodynamic monitoring of PA pressure IIb

should be considered in symptomatic patients with HF, NYHA class III and an HFH in the past 12 months in order to reduce the risk of HFH.

Specific conditions—Section 12

or II symptoms to reduce symptoms, CV

hospitalization and mortality.

variant or wild-type transthyretin cardiac amyloidosis and NYHA class I–III is recommended to reduce progression of symptoms and the risk of

Tafamidis is recommended in patients with wtTTR-CA and NYHA class I or II symptoms to reduce symptoms, CV hospitalization and

Treatment with a TTR silencer (vutrisiran) or stabilizer (tafamidis or acoramidis) for patients with

CV hospitalization and all-cause death.

mortality. ACE-I angiotensin-converting enzyme inhibitor; AF, atrial fibrillation; ARNI, angiotensin receptor–neprilysin inhibitor; AV, atrioventricular; BTC, bridge to candidacy; BTD, bridge to decision; BTR, bridge to recovery; BTT, bridge to transplantation; CAD, coronary artery disease; CCS, chronic coronary syndrome; CMR, cardiac magnetic resonance; CRT, cardiac resynchronization therapy; CV, cardiovascular; DCM, dilated cardiomyopathy; FMT, foundational medical therapy; HF, heart failure; HFH, heart failure hospitalization; HFmrEF, heart failure with mildly reduced ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; hTTR-CA, hereditary transthyretin cardiac amyloidosis; IABP, intra-aortic balloon pump; LGE, late gadolinium enhancement; LV, left ventricular; LVAD, left ventricular assist device; LVEF, left ventricular ejection fraction; MCS, mechanical circulatory support; MI, myocardial infarction; MRA, mineralocorticoid receptor antagonist; MT, medical therapy; nsMRA, non-steroidal mineralocorticoid receptor antagonist; NYHA, New York Heart Association; OMT, optimal medical therapy; PA, pulmonary artery; QoL, quality of life; RV, right ventricular; SAVR, surgical aortic valve replacement; sMRA, steroidal mineralocorticoid receptor antagonist; TAVI, transcatheter aortic valve implantation; TTR, transthyretin; wtTTR-CA, wild-type transthyretin cardiac amyloidosis. a Class of recommendation. b Level of evidence.

3. Definition, epidemiology, and classifications 3.1. Definition of heart failure Heart failure is a clinical syndrome comprising signs and/or symptoms caused by structural and/or functional abnormalities of the heart that result in elevated intracardiac pressures and/or inadequate cardiac output at rest and/or during exercise.11 In addition to the subjective symptoms of HF, clinically assessed objective evidence of cardiogenic pulmonary and/or systemic congestion and diagnostic supportive tests are needed to reach the diagnosis (see Section 5).11

People who are in asymptomatic stages are not included under the above definition as having HF. They are defined as being at risk for HF (stage A) or having pre-HF (stage B) (see Section 3.3). Identification of the aetiology of the underlying cardiac dysfunction is not included in the definition of HF, although determining aetiology is clinically important as the specific pathology can determine subsequent treatment and prognosis. Specific investigations needed to identify underlying aetiologies are described in Section 5.

3.2. Epidemiology of heart failure The prevalence of HF is estimated to be 1%–3% in the general adult population, with significant geographical, age- and sex-related

Tafamidis is recommended in patients with genetic testing proven hTTR-CA and NYHA class I

and coronary anatomy suitable for revascularization, despite OMT including

to improve QoL and reduce the risk of HFH or death. Coronary revascularization is recommended in patients with HF, obstructive CAD, and persistent

Coronary revascularization should be considered to relieve persistent symptoms of angina (or an angina-equivalent) in patients with HFrEF, CCS,

selected patients with symptomatic AF and HFrEF

Page 16 · PDF

3.2.1. Epidemiology of heart failure phenotypes In population-based samples, nearly half of all HF cases have HF with preserved ejection fraction (HFpEF), and this proportion may be increasing due to better treatment of coronary artery disease (CAD) and the rising burden of hypertension, obesity, and other HFpEF risk factors.21 Patients with HFpEF are older and are more often female. The Swedish HF registry reported an average age at HFpEF onset of 77 years with 55% female.22 In patients with heart failure with reduced ejection fraction (HFrEF), 71% were male and the mean age at onset was 72 years.22 Several subtypes of HFpEF have been suggested, with up to 50% of patients having a predominantly metabolic/obesity subtype [younger, higher body mass index (BMI)] in some regions, and up to 50% with a predominantly ageing, vascular subtype [older, stiff arteries, high prevalence of chronic kidney disease (CKD)] in other regions.23,24 Heart failure with reduced ejection fraction is often subdivided into ischaemic vs non-ischaemic aetiologies, with approximately half of all cases being considered ischaemic.

3.2.2. Natural history and prognosis Although the mortality rates after HF onset have improved considerably over the past three decades, the 5-year overall survival rates are still <60%.25,26 For younger patients, data from Denmark suggest survival has improved with contemporary management, with a current 5-year mortality rate of 15% for patients <65 years and 39% for patients aged 65–79 years.25 In patients ≥80 years, improvements in mortality have also been observed, although these improvements are not as pronounced as those observed in younger patients, partly due to a greater burden of comorbidity and a greater proportion of non-CV mortality in the elderly.17,25,27 Mortality may be lower in HFpEF than HFrEF, but overall differences are small as patients with HFpEF are considerably older, and the risk of hospitalization is similar.28,29 Patients diagnosed with HF in an outpatient setting have better

prognosis than patients diagnosed during a HFH, and patients with repeated HFH have a particularly high risk of mortality.30,31 The overall burden of HF as well as HFH can be expected to rise over the next few decades due to greater survival, an ageing population, and greater prevalence of risk factors and obesity in the younger population.

3.3. Classifications 3.3.1. Classification based on left ventricular ejection fraction Traditionally, HF has been divided into distinct phenotypes based on the measurement of LVEF. In the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure, three different HF phenotypes were identified: HFrEF (LVEF ≤40%); HF with mildly reduced ejection fraction (HFmrEF, LVEF 41%–49%); and HFpEF (LVEF ≥50%).3 The rationale behind this classification relates to the inclusion criteria of the trials of therapies that improved outcomes in patients with HF and LVEF ≤40%. The HFmrEF phenotype was introduced to focus on patients usually not included in HFrEF trials. The nomenclature was changed from ‘mid-range’ to ‘mildly reduced’ to highlight that patients with HFmrEF are similar to patients with HFrEF in terms of both clinical characteristics, outcomes, and response to treatments.32,33 Patients with HFmrEF have similar underlying aetiology of HF to patients with HFrEF, and the pathophysiology of HFmrEF is more similar to HFrEF (reduced contractility and systolic dysfunction) than HFpEF (increased stiffness and diastolic dysfunction).34 In addition, the efficacy of medical treatment of HFmrEF is more similar to HFrEF than HFpEF.35–45 Finally, it is important to consider LVEF trajectories, as many patients with LVEF 41%–49% may experience a deterioration in LVEF.46 The Task Force for the 2026 ESC Guidelines for the management of heart failure has eliminated the phenotype of HFmrEF and reclassified HF based on a pathophysiological classification of HF, including two distinct phenotypes: (i) HFrEF: characterized by LVEF <50% and symptoms and/or signs of HF. (ii) HFpEF: characterized by LVEF ≥50% and symptoms and/or signs of HF and objective evidence of cardiac structural and/ or functional abnormalities consistent with the presence of left ventricular (LV) diastolic dysfunction/raised LV filling pressures, supported by raised natriuretic peptides. Using a single LVEF value as cut-point for distinguishing HFpEF and HFrEF is somewhat arbitrary and has to be evaluated in the clinical situation, as there is variability in measurement depending both on the modality and the interpreter. Furthermore, LVEF may be falsely high in certain situations, e.g. mitral regurgitation (MR). Natriuretic peptides may be used as supportive evidence for the diagnosis of HF. Importantly, drug and device therapies can lead to positive LV reverse remodelling in patients with HFrEF and, thus, improvement of LVEF. Patients with HFrEF and improved LVEF have a more favourable prognosis. However, it is important to ensure that these patients are still managed with optimal medical therapy except for selected patients. The current definition of improved LVEF requires an increase of at least 10% in LVEF (absolute) and must be at least above 40% (often normal).47

variations.12,13 Both the incidence and prevalence of HF are increasing with age and risk-factor burden, with wide variation depending on the population and setting studied and the diagnostic criteria used.14 In addition, several factors, such as level of education, income, neighbourhood deprivation, climate, and air pollution, influence the risk of HF, contributing to varying epidemiology worldwide.13 In European countries, current prevalance-estimates range from 12–58 cases per 1000 people.15 As a result of the growing cohort of older people in Western populations, the crude incidence of HF has been increasing and is currently 2–13 per 1000 person-years in Europe (ranging from <1 per 1000 person-years for people aged 45–54 years to >12 per 1000 person-years for people aged >74 years).16,17 However, age-adjusted HF incidence rates have been declining over the past three decades, probably because of better risk-factor control and treatment of CV conditions.15,17,18 Among younger adults, incidence rates of HF appear to be either increasing or stagnating. There are several possible explanations for this, including (i) a greater burden of CV risk factors, (ii) increasing numbers of patients with congenital heart disease reaching adulthood, and (iii) a change in surveillance patterns.16,19,20 Furthermore, the mortality of HF has improved, which has led to a higher prevalence of HF.13

Page 17 · PDF

3.3.2. Classification based on heart failure stages An additional classification based on HF stages has been proposed previously.4 The Task Force has included this classification as we focus more on prevention of HF and early diagnosis (Figure 2).

3.3.3. Other classifications of heart failure

3.3.4. Classifications of treatments in heart failure The term guideline-directed medical therapy (GDMT) was introduced in the 2013 ACCF/AHA Guideline for the management of heart failure and is the cornerstone of pharmacological treatment for patients with HF.49 The term was meant to represent optimal medical therapy primarily with a Class I recommendation, which at that time included treatment with angiotensin-

Figure 2 Heart failure stages and classifications. AMT, additional medical therapy; FMT, foundational medical therapy; GDIT, guidelinedirected interventional therapy; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; LVEF, left ventricular ejection fraction. aSee section 4.1. Not all will develop HF, but risk factor intervention may be warranted. bFor example, left ventricular hypertrophy, cardiac chamber enlargement, ventricular wall motion abnormality, myocardial tissue abnormality (e.g. evidence of myocardial oedema, scar/fibrosis abnormality by T2-weighted cardiac magnetic resonance imaging or late gadolinium enhancement imaging), valvular heart disease. cFor example, reduced left or right ventricular systolic function, evidence of increased filling pressures (by invasive or non-invasive measures), abnormal diastolic function. dEspecially in the setting of exposure to cardiotoxins. eFor details see Table 14.

Heart failure can also be classified according to clinical presentation: de novo (patients without a previous diagnosis of HF) vs pre-existing (patients with a diagnosis of HF), and chronic HF vs decompensated HF (DHF). Chronic HF may deteriorate to DHF. Details on the definitions and subtypes of DHF are provided in Section 7. Finally, an additional classification in isolated left-sided HF vs isolated right-sided HF vs combined left- and right-sided HF can be used. The main aetiology of chronic right-sided HF is LV dysfunction-induced pulmonary hypertension [World Health

Organization (WHO) group 2] leading to combined left- and right-sided HF. However, there are a number of causes of isolated right-sided HF, e.g. right ventricular (RV) myocardial infarction (MI); arrhythmogenic RV cardiomyopathy (ARVC); pulmonary hypertension WHO groups 1, 3, 4, and 5; and tricuspid or pulmonary valve regurgitation. Diagnosis and management of chronic right-sided HF is covered comprehensively in a recent Heart Failure Association (HFA) position paper.48

Page 18 · PDF

Foundational medical therapy (FMT) constitutes the foundation of any HF management. Foundational medical therapy is defined as medical therapy with a guideline Class I recommendation for the treatment of the general HF population, with convincing evidence of an improvement in morbidity and/or mortality. In this guideline, FMT will include beta-blocker, ACE-I/ARNI/ARB, MRA, and SGLT2-I for HFrEF, and MRA and SGLT2-I for HFpEF. The term ‘optimal FMT’ may be used for FMT at the highest tolerated doses according to the guideline-recommended target doses (see Section 6.1). Medical therapies with a Class I recommendation only for specific subsets of patients with HF are not included in the definition of FMT. Additional medical therapy (AMT) is defined as all other medical therapies that receive a Class IIa/IIb recommendation OR a Class I recommendation with proven effect only on symptoms and/or quality of life (QoL) OR a Class I recommendation in specific subsets of patients/HF phenotypes. Guideline-directed medical therapy therefore covers both FMT and AMT. Guideline-directed interventional therapy (GDIT) includes all cardiac implantable electronic devices (CIED) and interventional therapies that have a recommendation in the guidelines.

       

Figure 3 New nomenclature for heart failure therapies. Guideline-directed medical therapy (GDMT) includes foundational medical therapy (FMT) and additional medical therapy (AMT). Guideline directed interventional therapy is abbreviated as GDIT.

converting enzyme inhibitors (ACE-Is)/angiotensin II receptor blockers (ARBs), beta-blockers, and mineralocorticoid receptor antagonists (MRAs) for HFrEF. Since 2013, there have been further advances in the management of patients with HF. Class I recommendations have now been presented for the use of angiotensin receptor–neprilysin inhibitors (ARNIs) and sodium– glucose co-transporter 2 inhibitors (SGLT2-Is) in HFrEF. Furthermore, there are now data to support Class I recommendations for the use of SGLT2-Is and MRAs in HFpEF. Although these foundational therapies are crucial to improving the prognosis in HF, many other pharmacotherapies have guideline recommendations, e.g. ivabradine, vericiguat, cardiac glycosides, and, more recently, glucagon-like peptide-1 receptor agonists (GLP-1 RAs). All of these therapies could be viewed as GDMT but are currently not included in the definition of GDMT. Furthermore, the use of the term GDMT ignores the crucial role of devices that work in synergy with medical therapy and new procedural therapies with effect on patient-reported outcomes, morbidity and mortality. The current Task Force has decided to introduce new classifications to describe medical, device, and procedural therapies in HF (Figure 3). These classifications are designed to be dynamic, so the terms can remain contemporary over time as new therapies may be easily incorporated into the terms.

Page 19 · PDF

4. Prevention of heart failure 4.1. Patients at risk of heart failure (stage A heart failure) 4.1.1. Cardiometabolic risk factors

4.1.2. Risk scores for individuals without heart failure To assist in more individualized HF risk estimation, the use of risk scores may be considered. In addition to risk scores to predict HFH and mortality among ambulatory patients with established HF77–80 several risk scores for primary HF prevention have been developed81–83. The American Heart Association (AHA) PREVENT-HF risk score81 and the ESC SCORE2-HF82 were both derived to estimate risk in people without pre-existing HF over a 10-and 30-year horizon. The ESC risk scores have been calibrated for low-, moderate-, high-, and very high-risk countries to fit the European population. The ESC SMART2-HF risk score83 was derived to estimate 10-year risk of HF in people

4.1.3. Lifestyle-related factors 4.1.3.1. Diet and physical activity Epidemiological studies have shown that diets high in sugars, saturated fats, refined grains, and processed food are associated with increased HF risk (especially HFpEF).84–90 In contrast, adherence to a diet rich in vegetables, nuts, whole grains, fish, and unsaturated fats have been associated with lowered HF risk.84,87 However, a secondary analysis of the PREDIMED trial comparing a Mediterranean diet (with olive oil vs nuts) to a lowfat diet in individuals at high risk of CVD did not show a significant difference in HF incidence between the groups over a median follow-up of 4.8 years.89 Similarly, sedentary behaviour and physical inactivity are strong risk factors for especially HFpEF development60,91, but no randomized controlled trials (RCTs) have investigated the role of physical activity for the prevention of HF.91–93 Recommendations on exercise type and intensity to promote general CV health are outlined in the 2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease.94

4.1.3.2. Smoking, alcohol, and substance abuse Smoking cessation has been shown to reduce HF risk over time in epidemiological studies and should be encouraged in all individuals.95–97 Similarly, heavy alcohol use is associated with increased risk of HF and is discouraged, whereas light-to-moderate intake has shown more mixed data with regard to HF risk.98 Any form of substance abuse, recreational or continuous, with drugs such as cocaine, amphetamine, and anabolic steroids is associated with increased risk of cardiomyopathy and HF.99–101 If use is suspected, this should be addressed with the patient and advised against. Recommendation Table 1 — Recommendations for prevention of heart failure (see Evidence Tables 1–15) Recommendations

Strict blood pressure control (systolic blood pressure target <130 mmHg) is recommended in patients with hypertension or stage B HF to reduce the risk of HF.63–69,102 An SGLT2-I is recommended in patients with T2DM at risk of HF (multiple ASCVD risk factors or established ASCVD) to reduce the risk of HF and CV death.103 An SGLT2-I is recommended in patients with T2DM and CKDc to reduce the risk of HF or CV death.104 Finerenone is recommended in patients with T2DM and CKDd to reduce the risk of HF.105–108

Diabetes, hypertension, obesity, and smoking account for approximately 50% of all HF events on a population-based level, ranging from 30%–40% among the oldest individuals (over 75 years) to 75%–80% among individuals aged <55 years, and are similar for HFpEF and HFrEF.50–52 These risk factors often cluster within the same individuals and tend to be stable over the life course unless intervened upon.53–56 Unhealthy lifestyle changes have led to a rising incidence and prevalence of obesity, hypertension, and type 2 diabetes over the past decades in many regions across Europe, particularly among young to middle-aged adults.57–59 Concomitantly, increases have been observed in the incidence rates of HF among young adults, underscoring the need for earlier and better prevention strategies on a population-based level.16,19,20 As the risk of HF is related to both risk-factor burden (intensity) and risk-factor duration (exposure time), early risk-factor management should be considered for younger people with longer anticipated exposure time. Personalized HF risk estimations (see Section 4.1.2) may aid clinicians and patients in discussions, management, and treatment decisions. Specific recommendations on the management of obesity, hypertension, and diabetes are outlined in the ESC guidelines on prevention of CV disease (CVD), hypertension, and diabetes, respectively.60–62 For hypertension, most evidence supports targeting a blood pressure <130 mmHg to reduce HF risk, although there are likely additional benefits of achieving lower treatment targets if tolerated.63–69 For diabetes, glucose-lowering drugs without proven HF safety should be avoided,70 and among those at particular risk of HF [especially in the presence of atherosclerotic CVD (ASCVD)], SGLT2-Is and GLP-1 RAs have been shown to lower risk of HFH and CV death.71–73 For obesity, declines in fat mass and waist circumference, but not lean mass, lowers HF risk and should be targeted.74 High cholesterol levels increase the risk of HF mainly through CAD, and the use of statins has shown to modestly lower HF events in people at high risk of ASCVD and HF.75,76

with pre-existing ASCVD. These risk scores are described in Supplementary data online, Section S1 and Figure S1.